Lettres d'investissement
Plongez à la découverte de nos stratégies d’investissement avec nos experts
The Olympus of fraud
In 2011, it was revealed that Olympus, the Japanese optics manufacturer, was involved in a $1.7 billion fraud, one of the largest and longest in corporate history. The company's CEO, Michael Woodford, was among the first to raise the alarm and was dismissed after just two weeks in the role. Although Comgest did not hold Olympus in 2011, we believe the lessons learned from this scandal can guide future investment decisions.
EUROPE EQUITIES: HEALTHCARE - AN EASY PILL TO SWALLOW?
Around the world, people are living longer. As societies age, the demand for healthcare services is likely to grow. That’s why we view European medical devices, pharmaceutical products and healthcare technology as promising long-term investment opportunities.
European SMID Caps: Small is Beautiful
Smaller companies have underperformed in recent years as large-cap companies have recorded outsized returns. Despite this trend, we believe that there are several examples of smaller companies in Europe that possess the right mix of quality characteristics and growth drivers to potentially deliver substantial returns over the long run. At Comgest, we aim to build our portfolios with quality companies with enduring competitive advantages, irrespective of their size or market capitalisation.
RIDING ESG WAVES ACROSS THE GLOBE: THE CASE OF THE US AND INDIA
At Comgest, we see the parallels between surfing and our own quality growth investment approach. Just as experienced surfers may wait hours before paddling out into the water and selecting a wave, we typically conduct years of fundamental research to determine whether a company meets our quality growth criteria. Liudmila Strakodonskaya, ESG Analyst, and Xing Xu, ESG Analyst / Portfolio Manager, detail how environmental, social and governance (ESG) factors fit into our research, investment selection and portfolio management process, spanning from India to the United States.
CHINA EQUITIES: IS CHINA STILL INVESTABLE?
China’s late September stimulus measures took many investors by surprise. Misperceptions and fears have convinced many that China is no longer an investable market. Beyond the macroeconomic challenges and headlines, Comgest believes that China remains a great hunting ground for quality growth companies.
HUMAN CAPITAL: THE UNDERESTIMATED RESOURCE IN COMPANY VALUATION
Financial metrics are crucial for evaluating a company’s value, but they don’t tell the whole story, writes ESG Analyst/Portfolio Manager Petra Daroczi. Human capital – the knowledge and skills people acquire throughout their lives – can be a significant competitive advantage, much like traditional capital expenditures on goods and services.